CEO Abraham Ceesay was paid $6,265,174 in fiscal year 2025, ↓ down 36.3% from fiscal year 2024 (SEC filing 0001193125-26-171828 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$6,265,174 ↓ Abraham Ceesay total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
RAPP's next annual pay disclosure, estimated April 22, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Abraham Ceesay | $652,927 | $0 | $0 | $5,156,416 | $431,059 | $0 | $24,772 | $6,265,174 |
| Chief Executive Officer and Director | ||||||||
| Jeffrey Sevigny | 561,087 | 0 | 0 | 2,101,230 | 283,780 | 0 | 77,845 | 3,023,942 |
| Chief Medical Officer | ||||||||
| Troy Ignelzi | 519,846 | 0 | 0 | 1,710,773 | 249,600 | 0 | 25,920 | 2,506,139 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Abraham Ceesay | $6,265,174 | $9,839,157 | — | ↓ −3,573,983 |
| Jeffrey Sevigny | 3,023,942 | — | — | — |
| Troy Ignelzi | 2,506,139 | 2,464,371 | — | ↑ +41,768 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Rapport Therapeutics, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper RAPP reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the Rapport Therapeutics, Inc. Peer Teardown Report
$6,265,174 Abraham Ceesay total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 8, 2026 · Source: 0001193125-26-171828 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for RAPP
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order RAPP
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
Each company listed discloses RAPP in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named RAPP in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Get the Rapport Therapeutics, Inc. Executive Compensation Report
$1,500
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Abraham Ceesay | CEO | $6,265,174 |
| Jeffrey Sevigny | Chief Medical Officer | $3,023,942 |
| Troy Ignelzi | CFO | $2,506,139 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| James I. Healy | Independent Director | $235,355 |
| John Maraganore | Independent Director | $230,355 |
| Paul M. Silva | Independent Director | $147,927 |
| Raymond Sanchez | Independent Director | $137,927 |
| Reid Huber | Independent Director | $221,855 |
| Robert J. Perez | Independent Director | $141,927 |
| Steven M. Paul | Independent Director | $221,855 |
| Wendy B. Young | Independent Director | $136,927 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Third Rock Ventures V, L.P. | Greater-than-10% holder | 2026-05-07 | D | 271,495 | $40 | $10,892,651 | Common, indirect | Form 4 ↗ |
| Third Rock Ventures V, L.P. | Greater-than-10% holder | 2026-05-08 | D | 5,018 | 40 | 202,256 | Common, indirect | Form 4 ↗ |
| Third Rock Ventures V, L.P. | Greater-than-10% holder | 2026-05-11 | D | 133,618 | 40 | 5,377,323 | Common, indirect | Form 4 ↗ |
| Third Rock Ventures V, L.P. | Greater-than-10% holder | 2026-05-26 | D | 18,572 | 40 | 743,753 | Common, indirect | Form 4 ↗ |
| Wendy B. Young | Director | 2026-06-10 | A | 15,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Reid Huber | Director | 2026-06-10 | A | 15,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James I. Healy | Director | 2026-06-10 | A | 15,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul M. Silva | Director | 2026-06-10 | A | 15,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven M. Paul | Director | 2026-06-10 | A | 15,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert J. Perez | Director | 2026-06-10 | A | 15,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Maraganore | Director | 2026-06-10 | A | 15,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Raymond Sanchez | Director | 2026-06-10 | A | 15,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Abraham Ceesay | Director | 2026-06-29 | D | 7,344 | 40 | 292,062 | Common | Form 4 ↗ |
| Abraham Ceesay | Director | 2026-06-29 | D | 876 | 40 | 35,336 | Common | Form 4 ↗ |
| Cheryl Gault | Chief Operating Officer | 2026-06-30 | D | 3,308 | 42 | 139,506 | Common | Form 4 ↗ |
| Cheryl Gault | Chief Operating Officer | 2026-06-30 | D | 3,792 | 41 | 156,964 | Common | Form 4 ↗ |
| Cheryl Gault | Chief Operating Officer | 2026-06-30 | D | 1,900 | 40 | 76,174 | Common | Form 4 ↗ |
| Cheryl Gault | Chief Operating Officer | 2026-06-30 | D | 1,000 | 43 | 43,155 | Common | Form 4 ↗ |
| Abraham Ceesay | Director | 2026-07-14 | D | 5,481 | 40 | 217,715 | Common | Form 4 ↗ |
| Abraham Ceesay | Director | 2026-07-14 | D | 2,729 | 41 | 110,722 | Common | Form 4 ↗ |
| Abraham Ceesay | Director | 2026-07-27 | D | 7 | 43 | 299 | Common | Form 4 ↗ |
| Abraham Ceesay | Director | 2026-07-27 | D | 2,203 | 42 | 92,762 | Common | Form 4 ↗ |
| Abraham Ceesay | Director | 2026-08-10 | D | 8,370 | 47 | 391,280 | Common | Form 4 ↗ |
| Abraham Ceesay | Director | 2026-08-10 | D | 14,171 | 46 | 651,492 | Common | Form 4 ↗ |
| Abraham Ceesay | Director | 2026-08-11 | D | 19,500 | 48 | 936,846 | Common | Form 4 ↗ |
| Abraham Ceesay | Director | 2026-08-11 | D | 5,794 | 49 | 281,721 | Common | Form 4 ↗ |
| Abraham Ceesay | Director | 2026-08-11 | D | 3,664 | 47 | 171,837 | Common | Form 4 ↗ |
| Krishnaswamy Yeleswaram | Chief Development Officer | 2026-08-19 | D | 404 | 50 | 20,160 | Common | Form 4 ↗ |
| Krishnaswamy Yeleswaram | Chief Development Officer | 2026-08-24 | D | 13,160 | 50 | 657,978 | Common | Form 4 ↗ |
| Krishnaswamy Yeleswaram | Chief Development Officer | 2026-08-25 | D | 20,799 | 50 | 1,046,421 | Common | Form 4 ↗ |
| Krishnaswamy Yeleswaram | Chief Development Officer | 2026-08-25 | D | 16,201 | 51 | 827,184 | Common | Form 4 ↗ |
| Abraham Ceesay | Director | 2026-08-25 | D | 18,921 | 50 | 937,957 | Common | Form 4 ↗ |
| Abraham Ceesay | Director | 2026-09-08 | D | 1,069 | 46 | 49,190 | Common | Form 4 ↗ |
| Abraham Ceesay | Director | 2026-09-08 | D | 7,141 | 46 | 325,308 | Common | Form 4 ↗ |
| Abraham Ceesay | Director | 2026-09-23 | D | 1,952 | 39 | 76,230 | Common | Form 4 ↗ |
| Abraham Ceesay | Director | 2026-09-23 | D | 43 | 41 | 1,765 | Common | Form 4 ↗ |
| Abraham Ceesay | Director | 2026-09-23 | D | 215 | 40 | 8,570 | Common | Form 4 ↗ |
| Cheryl Gault | Chief Operating Officer | 2026-09-30 | D | 2,075 | 34 | 70,043 | Common | Form 4 ↗ |
| Cheryl Gault | Chief Operating Officer | 2026-09-30 | D | 7,925 | 33 | 261,813 | Common | Form 4 ↗ |
| Abraham Ceesay | Director | 2026-10-06 | D | 3,375 | 32 | 108,106 | Common | Form 4 ↗ |
| Abraham Ceesay | Director | 2026-10-07 | D | 1,147 | 31 | 35,167 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Troy Ignelzi | OPTION | 2025-02-03 | — | — | 142,000 | — | $1,710,773 |
| Abraham Ceesay | OPTION | 2025-02-03 | — | — | 428,000 | — | 5,156,416 |
| Jeffrey Sevigny | OPTION | 2025-03-31 | — | — | 300,000 | — | 2,101,230 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Troy Ignelzi | $0 | $0 | $1,710,773 | 0.0% |
| Abraham Ceesay | 0 | 0 | 5,156,416 | 0.0% |
| Jeffrey Sevigny | 0 | 0 | 2,101,230 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jeffrey Sevigny | Option | 300,000 | 9.56 | — |
| Abraham Ceesay | RSU | 104,914 | — | 3,183,091 |
| Abraham Ceesay | Option | 331,655 | 17 | — |
| Abraham Ceesay | RSU | 107,500 | — | 3,261,550 |
| Troy Ignelzi | Option | 168,513 | 1.8 | — |
| Troy Ignelzi | Option | 50,854 | 17 | — |
| Troy Ignelzi | Option | 47,760 | 9.6 | — |
| Jeffrey Sevigny | Option | 6,349,214 | 12.23 | — |
| Abraham Ceesay | Option | 329,917 | 16.6 | — |
| Abraham Ceesay | Option | 109,918 | 1.8 | — |
| Troy Ignelzi | Option | 109,459 | 16.6 | — |
| Abraham Ceesay | Option | 143,071 | 9.6 | — |
Our executive compensation philosophy is to provide a competitive and market-based total compensation program to attract, motivate, and retain our executive team. Our compensation is based heavily on performance, which aligns with our goal to drive long-term growth and value creation.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon PLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| James I. HealyIndependent · Audit · Compensation (Chair) | $57,500 | $0 | $177,855 | $0 | $0 | $235,355 |
| John MaraganoreIndependent · Audit · Compensation | 52,500 | 0 | 177,855 | 0 | 0 | 230,355 |
| Steven M. PaulIndependent · Nominating/Governance · Science and Technology | 44,000 | 0 | 177,855 | 0 | 0 | 221,855 |
| Reid HuberIndependent · Science and Technology | 44,000 | 0 | 177,855 | 0 | 0 | 221,855 |
| Paul M. SilvaIndependent · Audit (Chair) · Nominating/Governance | 59,000 | 0 | 88,927 | 0 | 0 | 147,927 |
| Robert J. PerezIndependent · Compensation · Nominating/Governance (Chair) | 53,000 | 0 | 88,927 | 0 | 0 | 141,927 |
| Raymond SanchezIndependent · Compensation · Science and Technology | 49,000 | 0 | 88,927 | 0 | 0 | 137,927 |
| Wendy B. YoungIndependent · Science and Technology (Chair) | 48,000 | 0 | 88,927 | 0 | 0 | 136,927 |
| Abraham N. CeesayEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $407,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $407,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Rapport Therapeutics, Inc. | 2025 | Abraham Ceesay | $652,927 | $0 | $5,156,416 | $431,059 | $6,265,174 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Abraham Ceesay | DEF 14A | 2026-04-23 | 0001193125-26-171828 | Section “2025 Summary Compensation Table”. As printed: 6,265,174. Filing ↗machine: r2 · c26 · span 224488–224497 |
| 2 | Section 01, Jeffrey Sevigny | DEF 14A | 2026-04-23 | 0001193125-26-171828 | Section “2025 Summary Compensation Table”. As printed: 3,023,942. Filing ↗machine: r6 · c26 · span 233309–233318 |
| 3 | Section 01, Troy Ignelzi | DEF 14A | 2026-04-23 | 0001193125-26-171828 | Section “2025 Summary Compensation Table”. As printed: 2,506,139. Filing ↗machine: r4 · c26 · span 228855–228864 |
| 4 | Section 03, Troy Ignelzi OPTION | DEF 14A | 2026-04-23 | 0001193125-26-171828 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t61 · r4 · c15 · span 228009–228018 |
| 5 | Section 03, Abraham Ceesay OPTION | DEF 14A | 2026-04-23 | 0001193125-26-171828 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t61 · r2 · c15 · span 223642–223651 |
| 6 | Section 03, Jeffrey Sevigny OPTION | DEF 14A | 2026-04-23 | 0001193125-26-171828 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t61 · r6 · c15 · span 232463–232472 |
| 7 | Section 07, pay ratio | 10-K | 2026-03-10 | 0001193125-26-099360 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 8 | Section 08, James I. Healy | DEF 14A | 2026-04-23 | 0001193125-26-171828 | Section “Director Compensation”. As printed: 235,355. Filing ↗machine: t51 · r2 · c15 · span 166841–166848 |
| 9 | Section 08, John Maraganore | DEF 14A | 2026-04-23 | 0001193125-26-171828 | Section “Director Compensation”. As printed: 230,355. Filing ↗machine: t51 · r4 · c15 · span 169563–169570 |
| 10 | Section 08, Steven M. Paul | DEF 14A | 2026-04-23 | 0001193125-26-171828 | Section “Director Compensation”. As printed: 221,855. Filing ↗machine: t51 · r5 · c15 · span 170912–170919 |
| 11 | Section 08, Reid Huber | DEF 14A | 2026-04-23 | 0001193125-26-171828 | Section “Director Compensation”. As printed: 221,855. Filing ↗machine: t51 · r3 · c15 · span 168187–168194 |
| 12 | Section 08, Paul M. Silva | DEF 14A | 2026-04-23 | 0001193125-26-171828 | Section “Director Compensation”. As printed: 147,927. Filing ↗machine: t51 · r8 · c15 · span 174995–175002 |
| 13 | Section 08, Robert J. Perez | DEF 14A | 2026-04-23 | 0001193125-26-171828 | Section “Director Compensation”. As printed: 141,927. Filing ↗machine: t51 · r6 · c15 · span 172280–172287 |
| 14 | Section 08, Raymond Sanchez | DEF 14A | 2026-04-23 | 0001193125-26-171828 | Section “Director Compensation”. As printed: 137,927. Filing ↗machine: t51 · r7 · c15 · span 173629–173636 |
| 15 | Section 08, Wendy B. Young | DEF 14A | 2026-04-23 | 0001193125-26-171828 | Section “Director Compensation”. As printed: 136,927. Filing ↗machine: t51 · r9 · c15 · span 176344–176351 |
| 16 | Section 08, Abraham N. Ceesay | DEF 14A | 2026-04-23 | 0001193125-26-171828 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 17 | Section 02, Third Rock Ventures V, L.P. 2026-05-07 | Form 4 | 2026-05-11 | 0001193125-26-217092 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Third Rock Ventures V, L.P. 2026-05-08 | Form 4 | 2026-05-11 | 0001193125-26-217092 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Third Rock Ventures V, L.P. 2026-05-11 | Form 4 | 2026-05-13 | 0001193125-26-222185 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Third Rock Ventures V, L.P. 2026-05-26 | Form 4 | 2026-05-28 | 0001193125-26-245259 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Wendy B. Young 2026-06-10 | Form 4 | 2026-06-10 | 0001193125-26-266086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Reid Huber 2026-06-10 | Form 4 | 2026-06-10 | 0001193125-26-266090 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, James I. Healy 2026-06-10 | Form 4 | 2026-06-10 | 0001193125-26-266095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Paul M. Silva 2026-06-10 | Form 4 | 2026-06-10 | 0001193125-26-266099 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Steven M. Paul 2026-06-10 | Form 4 | 2026-06-10 | 0001193125-26-266129 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Robert J. Perez 2026-06-10 | Form 4 | 2026-06-10 | 0001193125-26-266147 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, John Maraganore 2026-06-10 | Form 4 | 2026-06-10 | 0001193125-26-266155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Raymond Sanchez 2026-06-10 | Form 4 | 2026-06-10 | 0001193125-26-266080 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Abraham Ceesay 2026-06-29 | Form 4 | 2026-07-01 | 0001193125-26-292519 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Abraham Ceesay 2026-06-29 | Form 4 | 2026-07-01 | 0001193125-26-292519 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Cheryl Gault 2026-06-30 | Form 4 | 2026-07-01 | 0001193125-26-292546 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Cheryl Gault 2026-06-30 | Form 4 | 2026-07-01 | 0001193125-26-292546 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Cheryl Gault 2026-06-30 | Form 4 | 2026-07-01 | 0001193125-26-292546 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Cheryl Gault 2026-06-30 | Form 4 | 2026-07-01 | 0001193125-26-292546 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Abraham Ceesay 2026-07-14 | Form 4 | 2026-07-15 | 0001193125-26-304786 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Abraham Ceesay 2026-07-14 | Form 4 | 2026-07-15 | 0001193125-26-304786 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Abraham Ceesay 2026-07-27 | Form 4 | 2026-07-29 | 0001193125-26-323637 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Abraham Ceesay 2026-07-27 | Form 4 | 2026-07-29 | 0001193125-26-323637 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Abraham Ceesay 2026-08-10 | Form 4 | 2026-08-12 | 0001193125-26-346995 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Abraham Ceesay 2026-08-10 | Form 4 | 2026-08-12 | 0001193125-26-346995 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Abraham Ceesay 2026-08-11 | Form 4 | 2026-08-12 | 0001193125-26-346995 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Abraham Ceesay 2026-08-11 | Form 4 | 2026-08-12 | 0001193125-26-346995 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Abraham Ceesay 2026-08-11 | Form 4 | 2026-08-12 | 0001193125-26-346995 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Krishnaswamy Yeleswaram 2026-08-19 | Form 4 | 2026-08-20 | 0001193125-26-359189 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Krishnaswamy Yeleswaram 2026-08-24 | Form 4 | 2026-08-26 | 0001193125-26-368244 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Krishnaswamy Yeleswaram 2026-08-25 | Form 4 | 2026-08-26 | 0001193125-26-368244 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Krishnaswamy Yeleswaram 2026-08-25 | Form 4 | 2026-08-26 | 0001193125-26-368244 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Abraham Ceesay 2026-08-25 | Form 4 | 2026-08-26 | 0001193125-26-368285 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Abraham Ceesay 2026-09-08 | Form 4 | 2026-09-09 | 0001193125-26-386436 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Abraham Ceesay 2026-09-08 | Form 4 | 2026-09-09 | 0001193125-26-386436 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Abraham Ceesay 2026-09-23 | Form 4 | 2026-09-24 | 0001193125-26-401017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Abraham Ceesay 2026-09-23 | Form 4 | 2026-09-24 | 0001193125-26-401017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Abraham Ceesay 2026-09-23 | Form 4 | 2026-09-24 | 0001193125-26-401017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Cheryl Gault 2026-09-30 | Form 4 | 2026-10-01 | 0001193125-26-410734 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Cheryl Gault 2026-09-30 | Form 4 | 2026-10-01 | 0001193125-26-410734 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Abraham Ceesay 2026-10-06 | Form 4 | 2026-10-08 | 0001193125-26-417919 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Abraham Ceesay 2026-10-07 | Form 4 | 2026-10-08 | 0001193125-26-417919 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 59 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 60 | Section 09b board cost (computed) | Computed | — | — | Cash 407,000 + equity 0 + all other 0 = 407,000, summed across the director compensation table rows.machine: formula: Σ = 407,000 |
| 61 | Rapport Therapeutics, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-171828 | CEO total compensation as printed in Rapport Therapeutics, Inc.'s own proxy. As printed: 6,265,174. Filing ↗machine: r2 · c26 · span 224488–224497 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the Rapport Therapeutics, Inc. Executive Compensation Report
$1,500